$ABUS

3 stories mentioning ABUSUpdated just now

Every FINWIRES story that references ABUS, newest first.

Sector Update: Healthcare Stocks Ease in Afternoon Trading

Healthcare stocks edged lower Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each down 0.1%.The iShares Biotechnology ETF (IBB) rose 0.4%.In corporate news, Legend Biotech (LEGN) could see pressures from competition and its recent leadership change, potentially weighing on its Carvykti myeloma therapy strategy, Oppenheimer said in a note. The firm downgraded Legend to perform from outperform and cut the price target to $40 from $75. Legend shares fell nearly 6%.Arbutus Biopharma (ABUS) shares dropped 2.5% after the company reported that it swung to a Q2 loss as revenue fell during the period.Definium Therapeutics (DFTX) shares jumped 6% after it said Wednesday its phase 3 trial of DT120 lysergide orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.

$ABUS$DFTX$LEGN

Sectors45m ago

Sector Update: Healthcare

Healthcare stocks were mixed Wednesday afternoon, with the NYSE Healthcare Index down 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Arbutus Biopharma (ABUS) shares fell 2.6% after the company reported that it swung to a Q2 loss as revenue fell during the period.

$ABUS

Sectors4h ago

Sector Update: Healthcare Stocks Lean Lower Premarket Wednesday

Healthcare stocks were leaning lower premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.4% and the iShares Biotechnology ETF (IBB) down 0.1%.Definium Therapeutics (DFTX) shares were up more than 16% after the company said its phase 3 Voyage study of DT120 lysergide orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.Arbutus Biopharma (ABUS) stock was down more than 3% after the company reported that it swung to a Q2 loss as revenue fell during the period.Natera's (NTRA) Latitude tissue-free assay for molecular residual disease detection will be used by Kupando Therapeutics in a phase 1 clinical trial of its lead immunotherapy candidate, KUP-101, Natera said. Shares of Natera were up more than 1% pre-bell.

$ABUS$DFTX$IBB$NTRA$XLV

Track with the FINWIRES app suite

FolioX

Track ABUS in your portfolio

WheelAI

Analyze ABUS options with the wheel strategy

StockInsider

See market sentiment on ABUS